Evidence map›Paper›PMID 36063980›Full record

ArticleNeuroscience letters2022

Targeting 5-HT

Velia S Vizcarra, Kara R Barber, Gabriela Franca-Solomon, Lisa Majuta, Angela Smith, Paul R Langlais, Tally M Largent-Milnes, Todd W Vanderah, Arthur C Riegel

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuroscience letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Velia S VizcarraDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85721, USA.
Kara R BarberDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85721, USA; Comprehensive Pain and Addiction Center, University of Arizona Health Sciences, 85721, USA.
Gabriela Franca-SolomonDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85721, USA.
Lisa MajutaDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85721, USA.
Angela SmithDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85721, USA.
Paul R LanglaisDepartment of Medicine, Division of Endocrinology, University of Arizona College of Medicine, Tucson, AZ 85721, USA.
Tally M Largent-MilnesDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85721, USA; Neuroscience Graduate Interdisciplinary Program, University of Arizona, Tucson, AZ 85721, USA; Comprehensive Pain and Addiction Center, University of Arizona Health Sciences, 85721, USA; The Center of Excellence in Addiction Studies, University of Arizona, Tucson, AZ 85721, USA.
Todd W VanderahDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85721, USA; Neuroscience Graduate Interdisciplinary Program, University of Arizona, Tucson, AZ 85721, USA; Comprehensive Pain and Addiction Center, University of Arizona Health Sciences, 85721, USA; The Center of Excellence in Addiction Studies, University of Arizona, Tucson, AZ 85721, USA.
Arthur C RiegelDepartment of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85721, USA; Neuroscience Graduate Interdisciplinary Program, University of Arizona, Tucson, AZ 85721, USA; Comprehensive Pain and Addiction Center, University of Arizona Health Sciences, 85721, USA; The Center of Excellence in Addiction Studies, University of Arizona, Tucson, AZ 85721, USA; Department of Neuroscience, College of Science, University of Arizona, Tucson, AZ 85721, USA; James C. Wyant College of Optical Sciences, The University of Arizona, Tucson, AZ 85721, USA. Electronic address: ariegel@arizona.edu.
University of Arizona · US

Funding

The Center of Excellence in Addiction Studies (CEAS)P30DA051355 · NIDA · UNIVERSITY OF ARIZONA · PI MILNES, TALLY MARIE · 2021 to 2025
$6.7M
THE ROLE OF RYANODINE RECEPTORS IN DRUG SEEKINGR01DA046476 · NIDA · UNIVERSITY OF ARIZONA · PI RIEGEL, ARTHUR C · 2018 to 2022
$1.9M
Primary Afferent Transmission in the Trigeminal Dorsal HornF32DE022499 · NIDCR · OREGON HEALTH & SCIENCE UNIVERSITY · PI MILNES, TALLY MARIE · 2011 to 2014
$127k
NIDA NIH HHS P30 DA051355NIDA NIH HHS R01 DA046476NIDCR NIH HHS F32 DE022499
6 · The paper itself

Abstract

Chronic pain remains a disabling disease with limited therapeutic options. Pyramidal neurons in the prefrontal cortex (PFC) express excitatory G

Indexed as

Chronic PainNeuralgiaAnimalsHyperalgesiaPrefrontal CortexProteomicsRatsRNA, MessengerSerotoninRNA, MessengerSerotonin5-HT(2A)RKv7 ion channelsPainPrelimbic cortexRetigabineSpared nerve injury (SNI)

Identifiers

PMID36063980
PMCPMC10088904
OpenAlexW4294550774

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.